戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 al NK-AML population (p = 0.03, censoring at allotransplant).
2 g cause of morbidity and mortality following allotransplant.
3 ow and its environment in a composite tissue allotransplant.
4  recurrence and will not be offered a repeat allotransplant.
5 used myeloablative conditioning regimens for allotransplants.
6  major histocompatibility complex mismatched allotransplants.
7 rejection of minor antigen disparate cardiac allotransplants.
8 and tapered corticosteroids, comparable with allotransplants.
9 n the elimination of malignant disease after allotransplants.
10 (-) mice that spontaneously accepted a heart allotransplant and displayed donor-specific tolerance al
11                 Immediately before the islet allotransplant and for 6 additional days, primates were
12      Upon tamoxifen-induced mutp53 ablation, allotransplanted and autochthonous tumours curb their gr
13 inal organs with multiple vascular composite allotransplants and tissues.
14                        Rats received corneal allotransplants and were killed during acute rejection.
15    Nonrejection causes of graft loss between allotransplants and xenotransplants differed; infection
16                         Seventy-six hemiface allotransplants, between ACI (RT1) donors and Lewis (RT1
17  resulted in 100% survival of mice receiving allotransplants challenged with an otherwise invariably
18                  As with recipients of other allotransplants, CTA recipients can experience rejection
19 donor-specific tolerance to composite tissue allotransplants (CTAs).
20                      At postoperative day 7, allotransplants developed moderate rejection as determin
21                                              Allotransplanted dogs that developed AR (n=8) and CR (n=
22 CNA staining in lung cultures from rejecting allotransplanted dogs was significantly greater than tha
23 g the potential for better outcomes in islet allotransplant for type 1 diabetes mellitus with refinem
24 al rates of insulin independence after islet allotransplant for type 1 diabetes, long-term islet func
25      We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC;
26 mechanistic pathway that protects the kidney allotransplant from rejection through a process we call
27 isolate human pancreatic islets intended for allotransplants generates a product that is hampered by
28 bserved after USPIO injection into rats with allotransplanted hearts.
29        The final questionnaire, named Kidney AlloTransplant Immunosuppressive Therapy Adherence (KATI
30                 The self-administered Kidney AlloTransplant Immunosuppressive Therapy Adherence (KATI
31 n cold University of Wisconsin solution, and allotransplanted into recipient dogs for either 4 hr (gr
32                         The mucosa of facial allotransplants is one of the primary targets of rejecti
33  (2) proliferation is increased in rejecting allotransplanted lungs, (3) endothelin-A receptors media
34 lin 3 were reduced in bronchi from rejecting allotransplanted lungs.
35 rade of rejection was 2.74+/-0.17 (n= 19) in allotransplanted lungs; evidence of infection was presen
36   We've established a nonhuman primate islet allotransplant model to address questions such as whethe
37     In a preclinical, nonhuman primate islet allotransplant model, the authors evaluated a novel immu
38 r rapid and stable tolerance induction in an allotransplant model.
39 stringent preclinical nonhuman primate heart allotransplant model.
40 ant survival in a rodent orthotopic hindlimb allotransplant model.
41 aftment/tolerance in exceptionally stringent allotransplant models by (1) limiting the early expansio
42 receptor blockade in mouse cardiac and islet allotransplant models has led to long-term engraftment a
43  for rapid and stable tolerance induction in allotransplant models.
44 r resulted in prolonged islet survival in an allotransplant mouse model.
45 cluded 17 articles that described changes in allotransplanted mucosa of fVCAs.
46              The failure of pancreatic islet allotransplants observed in almost all clinical attempts
47 possibility of performing a complex vascular allotransplant of all neck organs including skin.
48 f transplanted organs from the same species (allotransplant) or different species (xenotransplant).
49     One hundred thirty-two consecutive renal allotransplant patients, who underwent transplantation o
50                                       The 10 allotransplanted patients had very favorable outcomes (9
51                                 The UK islet allotransplant program is nationally funded to deliver o
52 particles at postoperative day 6, a group of allotransplanted rats was treated with cyclosporin A (3
53 lantation in a facial vascularized composite allotransplant recipient following irreversible allograf
54 jection surveillance, in Canada's first face allotransplant recipient.
55  by using data from 1827 HLA-matched sibling allotransplant recipients reported to the International
56 ecretion was observed in either the auto- or allotransplant recipients, whereas healthy control subje
57 d beta-cell phenotype in 2 intraportal islet allotransplant recipients.
58 raction of bronchi from autotransplanted and allotransplanted rejecting lungs.
59 rincipal cell death pathways contributing to allotransplant rejection and underpinning multiple autoi
60 spite their roles in autoimmune diseases and allotransplant rejection.
61   But how the innate immune cells respond to allotransplants remains poorly defined.
62 tched islets were rapidly rejected, and this allotransplant response was readily monitored via blood
63 valuable in many clinical situations such as allotransplants, some autoimmunities, as well as with so
64 F and short-term immunosuppressants prolongs allotransplant survival by inducing immunoregulatory eff
65 ants modulates vascularized composite tissue allotransplant survival in a rodent orthotopic hindlimb
66                    The results revealed that allotransplant survival was found to be significantly pr
67 aques under long-term immunosuppression, NHP-allotransplant survival was significantly inferior to cl
68 turation of APCs, and significantly improves allotransplant survival.
69             Treated hemiface/mandible/tongue allotransplants survived up to 385 days, without signs o
70 Sixty-seven percent of remitters received an allotransplant that delivered superior survival compared
71 ional successful multiple vascular composite allotransplants, thoracic, and abdominal organ recoverie
72                                              Allotransplants to apolipoprotein-E-deficient recipients
73 his shows that failure of orthotopic corneal allotransplants to elicit a CD4+ T-cell direct allorespo
74  bone marrow compartment in composite tissue allotransplants to potentially induce immune tolerance.
75 ay has implications for our understanding of allotransplant tolerance and tumor resistance to host im
76                                   Most islet allotransplant tolerance induction protocols have been t
77 lity and function of Treg cells for inducing allotransplant tolerance or treating autoimmune conditio
78 esus monkeys undergoing MHC-mismatched islet allotransplants treated with belatacept and the mTOR inh
79             The markedly reduced toxicity of allotransplants using nonmyeloablative regimens (mini-al
80 lerance to kidney and vascularized composite allotransplants (VCA).
81                                              Allotransplant was allowed after three consolidations.
82                        To test this, corneal allotransplants were performed in either inflamed (high-
83                           Orthotopic corneal allotransplants were performed in low-risk (nonvasculari
84 p I received composite musculocutaneous flap allotransplants (WF-->Lew) with immunosuppression allowi
85  group (54% vs 33%; p = 0.0087, censoring at allotransplant), while no difference was observed for DA